Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
MALVERN, Pa., Jan. 03, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led clinical-stage pharmaceutical company focused on defining new standards of care in medical and aesthetic dermatology, today announced that it plans to present at the 35th Annual J.P. Morgan Healthcare Conference. Aclaris President and Chief Executive Officer Dr. Neal Walker will present on Wednesday, January 11, 2016 at 3:30 pm PT (6:30 pm ET) at The Westin St. Francis in San Francisco.
A live audio webcast of the presentation will be available on the Investors section of the company's website, www.aclaristx.com. A replay will be available after the event.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
